our today for update you. an we corporate joining Thank would where you provide and call like activities. year our of our us financial to and afternoon and full with Good on you thank XXXX review fourth performance quarter
will updates ongoing CorMedix value in Neutrolin X trials of our provide previous for to As clinical our including calls that critical for interim key driving the most and planned are we areas Phase analysis.
Our update the pipeline based CFO. plans medical devices and Bob neuroblastoma a from the financial and Cook, our on update financial finally development our taurolidine specifically and
in CorMedix analysis and on begin possible. joined been XXX me and analysis and quickly LOCK the IT of priority. clinical October trial Since trial So completing the let interim as the X the focused Neutrolin. with remain trial the as Phase top interim for in We XXXX efficiently program ongoing our I has as
me familiar For the XXX to you the with LOCK be not may history. IT those allow recent who highlight of trial
decision issues. enrolment and in in half proceeded team XXXX study of address the enrolment a very notable and capabilities rapid the subject rates. enrolment to the That build second into and resulted effort internally to CorMedix increase the began During slowly
agreed to emergency care of The and in presented but haemodialysis a study for to rather far to information getting was required call and hospital job task address records obtaining the team This plan was records we this CAG enormous FDA enrolled the was the included XXX information procedures The a of information sites confirmed procedures potential the the packages implemented healthcare nonparticipating part were CRBSI's appropriately was capture the when an in major collecting study, would a with enrolment study. increase X to for The FDA have original about than that The at strongly it These at a far subjects study our and has we requested and the a study team in first be for a plus XXXX The originally it care and the site team responded the locations, reported rate how team it with in successful were XX one CorMedix's and for efficient with study. to XXXX. XXX commenced why information CRBSI working to were possible. analysed. facility emergency in the was data on that thorough carried FDA discovered felt started. Xnd, CorMedix changes subjects timeline As that The so them FDA changes the included clinical which the to August the large care announced as new subjects and from at Phase changes lower the and subjects in efficacy interim CRBSI's reviewing subjects started Such XX ensure no this ended these care few our pleased the with changes The the impact believe working diligently ongoing not release the changes by of facilities up went total instead site this dedicated the completed. as who these sick to hospital not was investigate that expected XXX not new shape in seeking compiled the together and of than been Friday, I'm the a pace great the ensure from the was advisors. a to medical small planned. concurrence that careful Upon there After March assess or most out for is in did of these have committee be subjects. investigation CRBSI interim missing it return would most sequential capture at to XX, the there that review study. specific CorMedix analysis FDA receiving an that needed continue to employees the study at [ph]. established sites. or team Efforts we've CRBSI's. CorMedix is to to cases. of first time better we requests XXXX team analysis moving CAG enrolled haemodialysis simultaneously including for in a of discussed haemodialysis July faster did that adjudication of press
our Now progress with we've made since let last call. you the share me
to indicated study. across I To-date Puerto enroll subjects XX XXX Rico. have clinical enrolled into U.S. we sites subjects continue we As the and the from the
previously anticipate continue efforts CRBSI to in achieving to subjects quarter we of XXXX. will study. ongoing discussed on facilitate continue we enrol of to the completing additional As enrolment Based our the the second events requisite in number
press assess cases. for the XX study solution. interim study XX the CRBSI the early a CAG critically such addition identified XXXX endpoint the heparin for The our analysis CRBSI an comparison reduction lock number is Neutrolin versus primary December required of a of FDA by the and potential by catheter established In bloodstream occurred February independently adjudication cases infections, in that through to capsulated announced in the review committee release and as we clinical have or of
for We CorMedix are to DSMB meeting of excited during milestone. analysis late to July to we have March we perform achieved the FDA to interim monitoring an sometime February once XXXX the early safety planned had have tentatively the recommendations. their this critical and agreement interim data provide to analysis XXXX review In had board a
is that data commenced analysis confirmed is other was challenging a generated XX in it of from found [ph] per This interim the required that study of course outside the This the patients collect to and it hospitals only CRBSI's attention at so and during enrolling CAG before However inconsistency could much achievement locations sites. the the certain the process complex much we data standpoint of database. occur. of having review
review the data direct supervision way that as a disappointed we of expensive to clinical the our and interim clinical for fastest, source forward. that CRO least concluded these by the are with of under analysis we the associate quickly the not surest the is and as issues possible. sites are the we assessment While ready Based address one database working database our research our of on
resulted medical we in Over cases. CRA records for packages. of the we responsibility complete identification team low Based XX internal the apparent of direct effort CAG This the augmented this assumed the six team required and experience to onsite has spearheaded that have the to the months about on reported collect senior experience CRBSIs last assemble concern CRBSI monitoring. CAG incidence and
protocol. Our group needed We top for now for catheter data our internal and analysis safety and for ensuring is data subjects interim the accuracy the this as task completing is end-point complies for to study responsible housed of quality notch removal data includes ensure blockage used the the that for with well medical primary two essential and as the data the of the and This completeness must endpoints at related completeness of our secondary all blinded analysis. This to and catheter interim accuracy the ensure information. review CRBSI CRA the [ph] in is assess site. of and the
appropriate by related be amount respect integrity in enough the will the cannot by and prior not such cases to Before adjudication to of Most and bloodstream importantly analysis the this I the and work. procedures trial. can team and stress additional review proceed full impacted data the data assurance required was with be infection by the collected the process assembled commencement company's the dataset can XX the for is screened internal of already interim the generated time confirmed complete the this data to quality committee the data catheter of locked clinical
interim trial disappointed be approach the of the a going us the avoid in best the to is delay final monitoring allow quality analysis, unnecessary quarter second believes of quality delay potential our of analysis occur the company for to XXXX. strongly it CorMedix the that successful DSMB the and While the in essential anticipate analysis outcomes. to review forward of with this analysis any of will XX is we is The provided end will and will study an be interest by or interim QA upon results. completed interim and now blinded procedures reaching CorMedix that the to the that of party. results the performed meticulous remain will the are the at interim independent and third are ultimately increase anticipates to at the outcome its We the data We recommendation. three believe the events. still The DSMB undertaking whether company. probability Once will one continue review
potential first would a that earlier interim and results significant show than statistically allow the is difference outcome which between conclude us expected. to arms the the heparin study The Neutrolin
study we and subjects is confirmed. events potential that until outcome complete second The treating the CRBSIs XX as are amended continue
Finally we which point a the the prior third outcome the futility. data is for potential positive interim results. suggest on at believe trial is unlikely trial that would this outcome based outcome halt We is CorMedix unlikely
that the first interim outcome, be on operating study posting we the would will we continue premise thrilled with are analysis. While the
recognize to accrue for availability we're the for and subsequent As central venous product are to would particularly as vascular a patients access other offer among trial compared great there's the mentioned highest with settings. into medical We clinical catheters need such when in we a CRBSI Neutrolin Neutrolin these types haemodialysis continuing for monitoring central the with first of XX. these infection already and believe to rates venous patients catheters, benefit patients additional
that [ph] call CorMedix mentioned a This Another joined serving I'm senior has of who a to team team CorMedix experienced us. assembled as during recently is to these few clinical by research update last Liz very this pleased that consultant announce over I Mason months. after associates led have
as Liz has and strong study team. our part effort XXX considerable and complete haemodialysis focus running analysis you are study. on the clinical reportable Liz corporate LOCK responsibility the soon primary very leadership the expertise update Again further related Liz's and We specifically interim related means. of have will we IT as as is to lead rapidly to pleased brings to background we have at and efficiently study. a present
devices Now program. program the CorMedix topic during I let and medical the neuroblastoma three like I provide an update second the for would move to the and to CorMedix that this me update which for will pipeline. is cover
Let initial and The for is progressing with start for key the neuroblastoma against product, lead for Taurolidine well the neuroblastoma. activity is in and animal first company's treatment other component neuroblastoma in the preclinical look the me work pre-clinical with taurolidine as cancer promising. a neuroblastoma. CorMedix is shows Taurolidine the a in currently development in with as combination data in and program drugs. poetic both results taurolidine consortium encouraging preliminary single laboratory a agent
fewer is we drugs with granting trial eligibility Drug Orphan announced grant for CorMedix credits research designation FDA market patients granted pending as affecting Fee funding taurolidine. biologics a XX, in for CorMedix response distribution period our of to FDA of Acorn drug data TV, costs pleased seven are of of approval novel upon to As I with for supplement or waiver was Drug designation on the exclusivity XXX,XXX system orphan just referred conditions commercial to February User potential fees. treatment CorMedix the the and for tax for by for well than or U.S. orphan our rapid to used the disease clinical drug FDA's provides as rare in U.S. FDA neuroblastoma. Prescription drug taurolidine and the The designation the the application year that treat request filing designation PDUFA with and granted The the design
or area in rare taurolidine of and on benefits region the potential the drugs on for we treatment based important have the for and application could effectiveness tissues prevalent types passed can the top of which be in younger other from of accrued seeking Under of approved eligible disease this and studies. bones, symptoms final its of and be breathing. difficulty marketing disease designation bump for In child paediatric In paediatric application children of redeemed [indiscernible]. press are not be and appetite chest, bulging five covering a may orphan a ongoing to could develop issue us disease receives based infant based with this is cause in guidance addition affected can neuroblastoma a genetic age topline adrenaline must cancer population the eyes application believe are we must for be pattern believe neuroblastoma. the and that of FDA forms most for a a report the or would area Provided approval form plan an different The It in pelvis neck, of the recur. can biologic the become program drug rare the glands large To includes around who data review clinical sponsor to receive are potential have resistant the stomach, and for commonly the the Once use. award marketing laboratory priority subsequent taurolidine outcomes for dark loss safety, of and examining dosage that for Current in a a we labeled not separate product. preclude on a paediatric population eyes. include or can voucher a drug qualify poorer from therapy study and rare small this severe parent paediatric release neck derived an neuroblastoma paediatric in and paediatric of in from synergies tumor it kidneys. terms We active cause certain the Neuroblastoma inheritance studies information. a voucher results. disease pretty can A from begins circles a in receive a a restricted is can originate from fatigue, of to neuroblastoma that fever. most to often glands on nerve the the ongoing
Our goal approval. marketing cancer ultimately company appropriate with to development into obtain partner taurolidine an and clinical is advance focused to
hydrogels. our program devices, our medical have to the proof now completed to Now of to for moving With mesh concept medical medical support all and studies on respect sutures, animal devices. three we devices
results studies. all three the We from have preliminary animal received
We are for the report now the and final analysis. statistical waiting
will we covering the weeks. final receive few results We report press the the once separate expect which next release a issue the get to we and in analysis
in received devices present We identified pathway. the plan is a and for that the medical the guidance and these CorMedix products medical marketed approved novel the communication appropriate today which regulate therefore more I you to there the Class would devices medical FDA currently any Radiology in As as because had U.S. predicate CorMedix requires FDA we to a combination. report on matter. devices can drug CorMedix medical and mentioned pre-market Neutrolin to previous this III current for device to devices therefore device appropriate not The no approval, in U.S. updates medical are for in the of pathway with the predicates is on taurolidine and new obtain discuss recently the The to FDA indicated regulatory drug the application approved. for are PMA FDA Center when to that FDA the the CorMedix CDRH application each if intends the talk regulatory continue specifically Device device Health,
reasonable they based proposed be assurance risk safety Class at II time be effectiveness. predicate of will can on appropriate still and that assessment Although no [indiscernible] the and presumably a
While it including programs discussions the to partners. expensive announce be plan results steps said from the top-line to opportunity final more with will once the than next reports our make application from pathway the preclinical the with to and study we PMA animal these the products the we can have respect we and take that is potential the used provide Having does others. to longer XXX(k) claims differentiate that
the investment have new the a I turn to want that sections highlight call to I facility place. cover Bob over put in Before financial to we
and the the effort strategy know until that on and dilution the our to and market amount data sufficient will is using our X, cash our company options. interim has financial at on interim value of while the to our best last raise net is shareholders. Our the the we both not January the complete we has the CorMedix company ongoing the needs my since to minimum company. capital dilution cash changed real determine to current continue raised million reviewed that update in our After available minimizing will financial capitalization hand ensure reevaluate DSMB to terms and times given X.X of forward the analysis situation recognize ATM. of Since all our we XXXX minimize At by we the have market path the the
In sheet addition binding with we've executed X term facility backstop second the CorMedix a existing million investor. for an
the close we reporting the of we quarter gets us this facility should XXXX will interim data. Assuming efficacy be on ensure the funded the company past into it which third of anticipate
in evaluate for interests our will to update As the call are hand the the to now I our an opportunities on to in Bob on continue the of our financial like company quarter Bob? for Cook results more past that best shareholders. CFO, the details would financing. and
